Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia

Amit Joharapurkar; Vrajesh Pandya; Harilal Patel; Mukul Jain; Ranjit Desai

doi:10.3389/fneph.2024.1459425

Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia

Front Nephrol. 2024 Oct 22:4:1459425. doi: 10.3389/fneph.2024.1459425. eCollection 2024.

Authors

Amit Joharapurkar¹, Vrajesh Pandya¹, Harilal Patel¹, Mukul Jain¹, Ranjit Desai¹

Affiliation

¹ Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, Gujarat, India.

Abstract

Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the preclinical and clinical profile of desidustat which led to its approval and clinical use in India.

Keywords: HIF; chronic kidney disease-induced anemia; hemoglobin; hepcidin; prolyl hydroxylase inhibitor.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.